Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
An important observation in our
2025-02-25

An important observation in our study is the lack of effect of paroxetine pretreatment alone on β2AR membrane expression, which suggests that paroxetine, and pharmacologic inhibition of GRK2 in general, does not directly induce changes in receptor dynamics. Rather, the decreased ligand-induced β-arr
-
br Expression of adiponectin mRNA in chickens We
2025-02-25

Expression of adiponectin mRNA in chickens We first sought to determine the nucleotide sequence of the chicken adiponectin cDNA. The open reading frame of the chicken adiponectin cDNA consists of 735 nucleotides that was 65–68% homologous to various mammalian adiponectin cDNAs (Maddineni et al.,
-
In this study high concentrations mM of thuringiensin were
2025-02-25

In this study, high concentrations (0.5–4 mM) of thuringiensin were required to stimulate the basal adenylate cyclase activity Fig. 2, Fig. 3, Fig. 4, but low concentrations of thuringiensin (1–100 μM) were sufficient to inhibit the forskolin-stimulated adenylate cyclase activity in rat cerebral cor
-
In the late s Solvay Pharmaceuticals discontinued
2025-02-25

In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the
-
A c and CD are expressed in a
2025-02-25

A2c and CD73 are expressed in a small population of OSNs with pear-shaped morphology. In spite of the expression of molecular markers of ciliated OSNs such as Golf, ACIII, and OMP [1, 17], these OSNs have an extremely short dendrite and are located in the superficial layer of OE. In addition to the
-
An alternative approach to the administration of ADO agonist
2025-02-25

An alternative approach to the administration of ADO agonists is to amplify the actions of endogenous ADO by inhibiting the ADO-metabolizing enzyme, ADO kinase (AK). Inhibition of AK has the net effect of potentiating the local concentration and the effects of ADO in the extracellular compartment. T
-
The pathogenesis of d penicillamine induced MG is not
2025-02-25

The pathogenesis of d-penicillamine-induced MG is not clear. The repertoire of anti-AChR Biotinylation crosslinker in d-penicillamine-induced MG has been shown to be similar to that in idiopathic MG in terms of AChR antigenic regions, suggesting a common immune mechanism (Tzartos et al., 1988). Abo
-
The fact that the BPloopAsn regains its Btx binding
2025-02-25

The fact that the α1-BPloopAsn141 regains its α-Btx binding with a Kd similar to that of the wild type α1 ECD [18], suggests that the AChBP Cys-loop does not interfere with the correct conformation of the mutant ECD. Data from analogous mutants of the human neuronal α7 subunit ECD showed improved li
-
In this study we make the first simultaneous recordings of
2025-02-25

In this study, we make the first simultaneous recordings of Z-DEVD-FMK release in multiple brain regions at a temporal resolution less than 1 s. One of the most striking findings is that acetylcholine release has a remarkably similar temporal profile in the mPFC and dHPC, suggesting a coordinated a
-
br Free entry equilibrium At stage of the game n
2025-02-25

Free entry equilibrium At stage 2 of the game, n ≥ 2 firms simultaneously decide whether or not to enter the industry. Market entry involves a sunk fixed cost f > 0, which we assume cannot be subtracted from the tax base. Our assumption reflects that deductions of market entry costs are often inc
-
Tautomycetin cell division inhibitor Previously we reported
2025-02-25

Previously, we reported that EL-Kras mice-fed diets rich in omega-6 FAs demonstrated increased pancreatic mast cell infiltration [16]. Significantly, increased infiltration of mast cells into the tumor microenvironment correlates with a poor prognosis [15]. Soucek et al.[25] demonstrated that mast c
-
U 18666A During the year study period
2025-02-25

During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk U 18666A of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects and decreased
-
The synthesis of compounds in
2025-02-25

The synthesis of compounds in which the ethyl linker has been modified to the carbamate and urea derivatives , and is shown in . Thus the diamine was reacted with glycolic Angiotensin 1/2 (1-9) to give the alcohol followed by Mitsunobu reaction with phthalimide to give . Deprotection with hydra
-
Polyphenols like flavonoids have the potential
2025-02-24

Polyphenols like flavonoids have the potential to penetrate into lipid bilayers which is vital for enabling protection against oxidation. Rosmarinic formyl is a natural polyphenol antioxidant isolated from Sphaeranthus amaranthoides. Polyphenols can inhibit the propagation of lipid oxidation by two
-
br Introduction Lung cancer is the leading cause of cancer
2025-02-24

Introduction Lung cancer is the leading cause of cancer death worldwide and is one of the most refractory of solid tumors along with pancreatic cancer. Since 1975 there have been notable improvements in the 5-year survival rate of patients with lung cancer [1]. This improvement in survival is tho
16210 records 21/1081 page Previous Next First page 上5页 2122232425 下5页 Last page